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Clinical significance of BRCA1 in breast and ovarian cancers 
 
Hereditary Breast and Ovarian Cancer (HBOC) is a syndrome 
resulting in an increased lifetime risk for developing breast and/or 
ovarian cancer.  The genetic basis of HBOC is usually an inherited 
germline mutation in one allele of either the BRCA1 or BRCA2 genes 
and subsequent loss of heterozygosity in somatic tissues [1].  Some of 
the trademarks of this syndrome include multiple family members 
with breast and/or ovarian cancer,  personal history of both breast 
and ovarian cancer, development of breast or ovarian cancer at an 
early age, and family or personal history of male breast cancer [1].   
Mutations in BRCA1 and BRCA2 are responsible for the 
majority of HBOC cases [1]. According to the literature, 10% of 
ovarian cancer cases and 3–5% of breast cancer cases are associated 
with BRCA1 or BRCA2 mutations [1].  In the presence of a BRCA1 
mutation, women have a 70-80% lifetime risk of developing breast 
cancer and a 50% risk of developing ovarian cancer.  Women carrying 
a BRCA2 mutation have a 50-60% lifetime risk of developing breast 
cancer and a 30% risk of developing ovarian cancer [2].  These genes 
belong to the tumor suppressor gene family for their capacity to repair 
damaged DNA through a process known as DNA double-strand 
break repair [3].  Therefore, an inherited mutation in either of these 
genes combined with loss of heterozygosity predisposes cells to 
chromosomal instability and greatly increases the probability of 
malignant transformation and cancer development.  Interestingly, 
multiple other potential functions have been proposed for the BRCA1 
and BRCA2 proteins that may have an impact on their tumor 
suppressor function [4]. 
 
 
 
 
 
 
 
 
 
 
 
The management of HBOC syndrome is an evolving area, and 
clearly much more research is needed to understand the molecular 
basis of cancer progression in these patients. The linkage of BRCA1  
and BRCA2 to early-onset hereditary breast cancer was discovered in 
1990 and 1994 respectively [5, 6].  Since then, BRCA genotyping is 
now used to determine patient counseling, management decisions, and 
prognosis of this syndrome [7].  However, inconsistent and limited 
data exist regarding the clinical course of BRCA-mutated patients 
after cancer develops [8].  A published meta-analysis for BRCA1-
related tumors reported a worse outcome among the breast cancer 
patients carrying a mutated BRCA gene [7], while BRCA1 mutated 
ovarian cancer patients had a more favorable clinical outcome [9].  
Other studies have reported that both BRCA1-mutated breast and 
ovarian tumors have a better outcome [8, 10].  This is likely due to 
increased sensitivity of BRCA mutated cells to chemotherapeutics 
targeting DNA such as anti-metabolites, alkylating agents, and 
topoisomerase inhibitors [11]. However, more research into the 
molecular basis by which the BRCA proteins function as tumor 
suppressors and the clinical significance is clearly needed. 
Over 1700 unique BRCA1 mutations have been reported to the 
Breast Cancer Information Core Database [12].  Of these mutations, 
858 have been confirmed as being “clinically significant.”  Clinically 
significant mutations cause an increased risk of cancer and result in a 
protein with reduced function or no protein product.  Three domains 
of the BRCA1 protein are mutated in cancer patients with relatively 
high frequency. These domains include the RING domain (exons 2-
7), a region encoded by exons 11-13, and the BRCT domain 
(exons16-24) (Figure 1).  The RING domain functions as an E3 
ubiquitin ligase.  The amino acids encoded by exons 11-13 contain 
protein binding domains for a number of diverse proteins.  The 
BRCT domain is a phosphoprotein binding domain with specificity 
for proteins phosphorylated by ATM/ATR kinases. 
Understanding the structural biology of BRCA1 and BRCA2 is 
important for elucidating both physiologic and pathophysiologic 
function of these proteins.  As shown in Table 1, multiple structures 
have been solved for the BRCA1 RING and BRCT domains and 
associated proteins, including clinically relevant mutants. 
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In this review we will focus on the structural basis by which the 
BRCA1 protein functions as a tumor suppressor, and highlight the 
importance of these studies to understanding the pathophysiology and 
clinical outcomes of breast and ovarian cancers. 
 
RING domain  
 
The RING (Really Interesting New Gene) domain of BRCA1 
consists of a RING finger and two flanking alpha helices 
encompassing amino acids 1-109 (exons 2-7) [13, 23].  Through 
seven conserved cysteine residues and one conserved histidine residue, 
the RING finger coordinates two Zn2+ atoms which stabilize the 
RING structure [24, 25].  The RING finger forms a globular 
structure with a core three strand β-sheet and a central helix, while the 
flanking helices align perpendicular to the RING finger (Figure 2).  
The RING finger, which is a highly conserved domain found in a 
large number of proteins, is responsible for the E3-ubiquitin ligase 
activity of BRCA1 [26].  The N and C-terminal helices are 
responsible for the interaction of BRCA1 with BARD1 (BRCA1 
Associated RING Domain protein 1), a major BRCA1 binding 
partner that also contains a RING domain [27].  The ubiquitin ligase 
activity of BRCA1 is dramatically increased by formation of the 
BRCA1/BARD1 heterodimer [28].  As with all E3-ubiquitin ligases, 
ubiquitination of a substrate can only occur through interaction with 
an E2 ubiquitin-conjugating enzyme.  UbcH5, as well as other E2 
enzymes, binds to the surface of BRCA1 opposite the binding 
interface with BARD1 [29].  The large number of cancer 
predisposing mutations that affect the interaction of 
BRCA1/BARD1 or BRCA1/UbcH5 as well as the RING E3 ligase 
function suggest that the ubiquitin ligase activity of BRCA1 is 
essential for its tumor suppressor function (but see [30]). 
Figure 1. BRCA1 mutations occur at the highest rates in the RING 
domain, exons 11-13 and the BRCT domain.  A) BRCA1 clinically relevant 
mutations from the Breast Cancer Information Core (BIC).  Fold increase in 
mutations were calculated as mutations per codon length of each 
exon/total mutations per total BRCA1 codons.  1.0 on the y-axis indicates 
the total average mutations per codon for BRCA1.  Corresponding 
domains are indicated above the graph.  B) Domain map of BRCA1. RING, 
serine containing domain (SCD), and BRCT domains are indicated. NES and 
NLS sequences are also depicted.  Horizontal solid black lines indicate 
protein binding domains for the listed binding partners.  Red circles mark 
phosphorylation sites. 
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We have gained the most information about the structure-
function of the BRCA1 RING domain from the structure of the 
BRCA1/BARD1 heterodimer.  BARD1 also contains a RING 
domain with sequence and structural homology to BRCA1, including 
two flanking alpha helices.  The N-terminal alpha-helix of BRCA1 
aligns in an antiparallel fashion with the C-terminal alpha helix of 
BARD1.  Conversely, the C-terminal alpha-helix of BRCA1 is 
antiparallel to the N-terminal alpha-helix of BARD1 (Figure 2) [13].  
The four helix bundle creates a large buried hydrophobic region and 
stabilizes the heterodimer, while interactions between the BRCA1 
RING finger and the flanking alpha-helices maintain the orientation 
of the RING finger with respect to the flanking alpha-helices.  The 
interaction between BRCA1 and BARD1 both increases the ubiquitin 
ligase activity of BRCA1 and causes the nuclear export sequence 
(NES), located on the C-terminal helix of the RING domain of both 
BRCA1 and BARD1, to be buried [13, 32, 33].  The buried NES in 
the four helix bundle results in nuclear retention of the two proteins.  
The four helix bundle contains the majority of the interactions 
between BRCA1 and BARD1, however a few inter-RING 
interactions may occur as well [13].  As stated above, the RING 
finger of BRCA1 consists of a small three strand antiparallel β-sheet 
and a central helix.  Two Zn2+ atoms stabilize the structure within the 
RING finger and are coordinated by Zn2+ binding loops named Site I 
and Site II.  Site I is made up of four cysteine residues, while Site II 
contains three cysteine residues and one histidine residue.  The Zn2+ 
binding residues are highly conserved and characteristic of RING 
fingers found in many other proteins.  Additionally, the spacing 
between the Zn2+ binding residues is conserved among many RING 
fingers.  Conversely, a central helix is present in some RING fingers, 
but not all [13].   
Ubiquitination of substrates occurs in a three-step process.  First, 
an E1 ubiquitin-activating enzyme activates a ubiquitin (Ub) 
molecule, which is transferred to an E2 ubiquitin-conjugating enzyme.  
The E3 brings together the E2 and substrate to complete the 
ubiquitination process.  The human genome encodes ~40 E2 
enzymes, which rely on ~1000 E3 ubiquitin ligases for their 
specificity [34].  RING E3 ubiquitin ligases, including BRCA1, act 
solely as scaffolds by binding to the E2 via the RING finger domain, 
while the substrate binds to another domain on the E3.  This brings 
the substrate close enough to the E2 to allow for transfer of Ub from 
the E2 to the substrate.  The presence of the E2 ubiquitin-
conjugating enzyme, UbcH5, dramatically increases BRCA1/BARD1 
ubiquitination activity in vitro [28].  NMR structures of 
BRCA1/BARD1/UbcH5c show that loops of UbcH5c bind to a 
groove formed by the two Zn2+ binding sites and the central helix of 
the RING finger of BRCA1, and that UbcH5c has no interaction 
with BARD1 [29].  Several other E2 proteins have been shown to 
interact with the BRCA1/BARD1 heterodimer in a yeast-two hybrid 
study [35].  Targets of BRCA1 E3 ligase activity in vivo include 
estrogen receptor-alpha, progesterone receptor, CtIP, and histone 
protein H2A with resulting alterations in gene activation, DNA 
repair, and DNA condensation [36-40]. 
BRCA1 is also subject to autoubiquitination in in vitro 
experiments. Depending on the specific E2 interaction, either mono 
or poly-autoubiquitination can occur.  Additionally, Lys63, Lys48 
and Lys6 polyubiquitin chains can be conjugated to BRCA1.  Two 
modes of BRCA1/BARD1 autoubiquitination have been established. 
“Substrate-specific” monoubiquitination by the E2s UbcH6, Ube2e2, 
UbcM2, Ube2w and UbcH5 result in the conjugation of a single Ub 
residue to BRCA1 [35].  “Ubiquitin-specific” E2s, Ubc13, Ube2k 
and UbcH5 recognize monoubiquitinated BRCA1 and stimulate the 
conjugation of Lys6, Lys48, and Lys63 polyubiquitin chains to 
BRCA1 [35]. Thus, different E2 enzymes mediate the mono and 
polyubiquitination of BRCA1 in vitro. 
 
Mutation of the cysteine residues that coordinate the Zn2+ atoms 
have been reported as clinically important, indicating that they result 
in altered function and an increased risk of cancer.  Mutation of 
residues in Site I result in altered folding of the RING domain [13].  
A more complete study of Site II residue mutations found altered 
structure by mass spectrometry and reduced Zn2+ binding at Site II 
[41] .  This study reported that BRCA1/BARD1 heterodimerization 
was not affected by Site II mutations, however a later study by the 
same group reported that several Site I and Site II mutations caused 
not only a decrease in ubiquitin ligase activity, but also a decrease in 
co-immunoprecipitation of BRCA1 and BARD1 [29].  These studies 
suggest that mutation of Site I and Site II residues may affect BRCA1 
ubiquitin ligase activity by either decreasing BRCA1/BARD1 
heterodimerization or BRCA1/UbcH5 interaction.  Another study 
has shown that the E3-ubiquitin ligase activity of BRCA1 is inhibited 
by platinum (Pt)-based alkylating chemotherapeutic drugs [42, 43].  
Cisplatin forms adducts through its Pt atom with His117 of BRCA1, 
causing conformational changes and inhibiting the E3-ubiquitin ligase 
activity in vitro [43].  Other Pt-based drugs had similar functional 
effects.  Transplatin, carboplatin and oxaliplatin all reduced the E3 
ligase activity of BRCA1 at therapeutically relevant concentrations 
[42].  The large number of RING domain mutations that result in 
increased risk of breast cancer and the effect of chemotherapeutic 
drugs on RING domain activity suggest an important role for the 
RING domain in tumor suppression (but see [30]). 
 
Exon 11-13 
 
Exons 11-13 cover over 65% of the sequence of BRCA1 and 
encode two nuclear localization sequences (NLS) and binding sites 
for several proteins including retinoblastoma protein (RB), cMyc, 
Rad50 and Rad51 (reviewed in [44]).  The amino acids encoded by 
Figure 2. BRCA1 RING domain.  The RING domain contains a RING finger 
and two flanking alpha helices.  The RING finger consists of a core of β-
strands, a central helix, and two Zn2+ binding sites.  BRCA1 (pink) forms a 
heterodimer with the RING domain of BARD1 (blue). Critical NES residues 
are highlighted in yellow.  N-termini of each strand are labeled.  Structural 
model is derived from PDB accession number 1JM7 and rendered using 
POLYVIEW-3D [31]. 
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these exons also contain portions of a coiled-coil domain which 
mediates interactions with PALB2, as well as a portion of a serine 
containing domain (SCD) that is phosphorylated by ATM (Figure 
3).  No atomic-level structures have been determined for exons 11-13 
of BRCA1.  Despite the fact that exons 11-13 contain a large 
percentage of the clinically relevant mutations, very little is known 
about the structure or function of this region when compared to the 
RING or BRCT domains [12].  Interestingly, BRCA1 exon 11-13 
binding partners are involved in a wide range of cellular pathways.  
Myc is a transcription factor for a large number of genes.  Rad50, 
Rad51 and PALB2 are involved in DNA repair.  RB controls cell 
cycle progression.  The large number of mutations occurring in this 
region, many with loss of large portions of sequence, suggests that this 
region is important for the tumor suppressor function of BRCA1.   
 
 
 
 
 
 
 
 
 
 
 
The phosphoprotein RB is a well-known tumor suppressor that 
controls growth by regulating progression through the cell cycle [45].  
BRCA1 interacts with the hypo-phosphorylated form of RB via 
BRCA1 exon 11. Specifically, amino acids 304-394 were found to be 
responsible for binding to the ABC domain of RB [46].  Over-
expression of BRCA1 in cells expressing wild type RB causes 
suppression of cell cycle progression.  Deletion of the region of 
BRCA1 that mediates BRCA1/RB binding inhibits BRCA1-
dependent suppression of cell cycle progression [46].  This suggests 
that the exon 11-mediated interaction between BRCA1 and RB 
causes cell cycle arrest through actions of RB.  This finding also 
indicates that exon 11 is responsible for BRCA1-dependent cell cycle 
arrest, and this may also be dependent on the BRCA1/RB 
interaction. 
 
Rad50 and Rad51 are two proteins involved in DNA repair.  
Rad50 functions in a complex that includes MreII and Nbs1.  This 
complex is involved in both non-homologous end joining (NHEJ) as 
well as homologous recombination (HR).  An interaction between 
BRCA1 and Rad50, and therefore with the Rad50/MreII/Nbs1 
complex, has been established.  This interaction requires BRCA1 exon 
11 amino acids 341-748 [47].  BRCA1 recruits the 
Rad50/MreII/Nbs1 complex to sites of DNA double strand breaks 
to facilitate DNA repair.  BRCA1-null mouse embryonic fibroblast 
cells exhibit decreased levels of NHEJ activity, which suggest that 
BRCA1 is involved in the NHEJ process through interaction with the 
Rad50/MreII/Nbs1 complex.  Rad51 is a homologue of the yeast 
protein RecA and binds to ssDNA, facilitating homologous 
recombination (HR).  BRCA1 is associated with Rad51 during both 
mitotic and meiotic cells via amino acids 758-1064 [48].  BRCA1 
association with Rad50 and Rad51 suggests a role for exon 11 in 
both NHEJ and HR processes of DNA repair.  
 
The transcription factor c-Myc also interacts with BRCA1.  
Reports have indicated that c-Myc promotes transcription of up to 
15% of the genome, making it a major hub for transcriptional 
activation [49].  BRCA1 has two c-Myc binding sites (known as 
MB1 and MB2).  MB1 is located only in exon 11 (a.a. 433-511) 
while MB2 is located in exons 8-11 (a.a. 175-303) [50].  In SVD-P5 
cells co-transformed with c-Myc/Ras, transfection with BRCA1 
significantly decreased the ability of these cells to form transformed 
foci [50].  This suggests that the transformation activity of c-
Myc/Ras is inhibited by BRCA1 expression.  Additionally, the 
transcriptional activity of Myc is decreased by BRCA1 [50].  Thus, 
suppression of the oncogenic activities of c-Myc may account for 
some of the tumor suppressor activity of BRCA1. 
 
Exon 11 contains two nuclear localization sequences (NLS).  
Amino acids 501-507 (NLS1) and 607-614 (NLS2) are both 
recognized by importin-α machinery to mediate BRCA1 transport 
from the cytosol to the nucleus.  While both sequences are recognized 
by importin-alpha, NLS1 is the most critical sequence because 
mutation of this sequence inhibits all interactions between BRCA1 
and importin-alpha [51].  Mutation of the NLS sequences results in 
altered subcellular localization of BRCA1, with a shift toward 
cytosolic localization.  Clearly, mutations of BRCA1 NLSs causing 
cytosolic expression of BRCA1 would decrease the tumor suppressor 
activity of BRCA1 due to the loss of BRCA1’s DNA repair activity 
and subsequent increase in unrepaired mutations and chromosomal 
abnormalities.   
 
A putative coiled-coil domain spanning exons 11-13 in BRCA1 
(a.a. 1364-1437) contains the binding site for PALB2.  At this site, 
PALB2 acts as a scaffold to bring together BRCA1 and BRCA2 to 
form a complex of the three proteins which is involved in HR during 
DNA repair.  Both BRCA1 and PALB2 contain coiled-coil domains 
that mediate the interaction of the two proteins.  Through modeling 
of the coiled-coil domain of BRCA1 and PALB2, the interaction sites 
were mapped to the predicted a-face of the PALB2 helix containing 
Lys14, Leu21, Tyr28, Leu35, and Glu42 and the predicted a and d-
faces of BRCA1 [52].  Mutations in the coiled-coil region of BRCA1 
led to the discovery of the PALB2 binding site on BRCA1, since 
mutations reported in this region (Met1400Val, Leu1407Pro, and 
Met1411Thr) inhibit interaction between BRCA1 and PALB2 [52].   
 
BRCA1 contains a domain called the serine cluster domain 
(SCD).  A portion of the SCD of BRCA1 is located in exons 11-13, 
and spans from amino acids 1280-1524.  The region has a 
concentrated amount of putative phosphorylation sites, and is 
phosphorylated by ATM/ATR kinases in vitro and in vivo.  ATM 
and ATR are kinases activated by DNA damage.  Phosphorylation of 
BRCA1 causes recruitment of BRCA1 to sites of double strand 
breaks.  SCDs are common in ATM/ATR targets including multiple 
DNA damage response proteins [53].  Serines 1189, 1457, 1524, and 
1542 can all be phosphorylated in vivo, while additional serines can 
be phosphorylated in vitro [54].  Mutation of these serine residues are 
seen clinically, and may affect localization of BRCA1 to sites of DNA 
damage and DNA damage response function.  
Figure 3.  BRCA1 exons 11-13 have multiple functions.  The amino acids 
encoded by BRCA1 exons 11-13 have binding domains for several proteins 
including retinoblastoma (RB), Rad 50, Rad51, c-Myc and PALB2 (a scaffold 
for BRCA2).  BRCA1 exons 11-13 also contain a nuclear localization signal 
(NLS) and a serine cluster domain (SCD). 
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BRCT domain 
 
The BRCA1 C-terminal (BRCT) domain was originally 
identified in BRCA1, but it is also a conserved domain in multiple 
other proteins (most being involved in DNA damage repair).  BRCT 
domains can occur as a single BRCT domain, as a tandem repeat (as 
found in BRCA1), multiple repeats, or fusions between two domains 
(reviewed in [55]). The BRCA1 BRCT domain mediates 
phosphoprotein interactions between BRCA1 and proteins 
phosphorylated by ATM and ATR, two kinases activated by DNA 
damage (reviewed in [56]).  BRCT domains are classified into two 
categories based on their ability to recognize phosphoproteins.  Class-
I BRCT domains can recognize phosphoserine (pSer) residues, while 
Class-II BRCT domains can recognize both pSer and 
phosphothreonine (pThr) residues.  The BRCA1 BRCT domain 
recognizes the sequence pSer-X-X-Phe in its phosphorylated binding 
partners, and is therefore a Class-I BRCT domain. Binding partners 
for the BRCA1 BRCT domain include BACH1, CtIP, and 
CCDC98/abraxas [57-59].  While the main function of the BRCA1 
BRCT domain is modulating interactions between BRCA1 and 
phosphoproteins, BRCT domains, including the BRCT domain of 
BRCA1, can also mediate DNA binding and non-phosphoprotein 
interactions [60]. 
 
Amino acids 1650-1863 of BRCA1 consist of two tandem 
BRCT repeats connected by a 22 amino acid linker [14].  Each 
BRCT repeat consists of three α-helices packed around a four strand 
β-sheet (Figure 4A).  The two BRCT repeats interact in a head-to-
tail fashion through the interaction between α-helix 2 of BRCT1, and 
α-helices 1 and 3 of BRCT2 through mainly hydrophobic residues.  
The architecture of the tandem BRCT allows the BRCA1 BRCT to 
recognize both a pSer and the 3+ aromatic residue in a bipartite 
manner in two separate recognition pockets in the cleft between 
BRCT1 and BRCT2 (Figure 4B) [15, 19] (also reviewed in [55]).  
The pSer residue forms hydrogen bonds with Ser1655 and Lys1702 
and the backbone amine group of Gly1656, all within the N-terminal 
BRCT1 [19].  The 3+ phenylalanine residue fits into the 
hydrophobic core created by the two BRCT repeats, while the main 
chain backbone of the 3+ phenylalanine forms hydrogen bonds with 
R1699 of α-helix 1 of the N-terminal BRCT domain (Figure 4C) 
[19].  The size and subsequent rigidity of the hydrophobic core of the 
interface between the two BRCT repeats dictates the strict consensus 
sequence required for substrate recognition by the BRCA1 BRCT 
domain.  The consensus sequence pSer-X-X-Phe facilitates 
recognition of targets such as CtIP, BACH1, and abraxas which are all 
phosphorylated in response to DNA damage (reviewed in [55]). 
The BRCA1 BRCT domain has also been shown to bind 
directly to DNA double strand breaks (DSB) by electron microscopy 
[60].  However, the in vivo relevance of this interaction is unknown.  
While structural studies of the interaction between the BRCA1 
BRCT domain and double strand breaks have yet to be carried out, 
models have been developed with predicted interactions between the 
BRCT of replication factor RFCp140 and DNA double strand 
breaks.  The BRCT domain of RFCp140 recognizes the terminal 5’ 
phosphate of a 3’ overhanging DNA double strand break, as well as 
the major groove of the DNA adjacent to the double strand break 
[61].  It is unknown whether or not the BRCT domain of BRCA1 
binds to DNA in a similar manner. BRCT domains have also been 
shown to interact with some proteins in a phosphorylation-
independent manner, however this has been much less studied and not 
well characterized in BRCA1 (reviewed in [55]).   
 
 
 
 
 
 
 
 
 
 
Multiple studies have found mutations in the BRCT domain of 
BRCA1 in breast and/or ovarian cancers [63-65].  Specifically, 
mutation of hydrophobic residues within the hydrophobic core of the 
BRCT domain inhibits the ability of BRCA1 to recognize 
phospholigands [19].  This would suggest that mutation of a residue 
required for recognition of a substrate would impede the ability of 
BRCA1 to carry out its role in the DNA damage repair pathway.  An 
interesting example causes BRCA1 to fall into a “similarity trap” 
[66].  Typically, phosphorylated p53 has a much higher binding 
affinity for 53BP1 (p53 binding protein 1), than BRCA1.  Both 
53BP1 and BRCA1 interact with p53 through their tandem BRCT 
domains, however with different affinities. Two cancer causing 
mutations in BRCA1, Phe1695Leu and Asp1733Gly cause BRCA1 
to bind p53 with similar affinity to 53BP1 [66].  This suggests that 
these mutations of BRCA1 in the BRCT domain could force BRCA1 
into a similarity trap, causing 1) BRCA1 to bind p53 with higher 
affinity than wild-type BRCA1, and 2) competition for 53BP1 
binding to p53.  Thus, it is likely that these mutations in the BRCA1 
BRCT domain lead to altered p53 function possibly contributing to 
the cancer phenotype.  Another study has shown that cancer causing 
mutations in other areas of the BRCA1 BRCT domain can alter the 
backbone structure of the BACH1 binding pocket [67].  This 
suggests that mutations that affect the BACH1 binding pocket are not 
limited to just the residues in direct contact with the phosphopeptide.  
The number of cancer causing mutations in this region suggests that 
this domain is critical for tumor suppression. 
 
Figure 4. BRCA1 BRCT tandem repeats recognize phosphoproteins.  A) 
BRCT1 and BRCT2 pack together in a head-to-tail orientation and are 
connected by a linker helix.  Helix 2 from BRCT1 and helices 1 and 3 from 
BRCT2 form a hydrophobic core and stabilize the structure.  Rendering 
was generated using POLYVIEW-3D [31].  Structural model is derived from 
PDB accession number 1T29.  B) The cleft between BRCT1 and BRCT2 
forms the binding pocket for proteins phosphorylated by ATM and ATR.  
The BRCA1 BRCT domains are shown in blue, and a fragment of BACH1 is 
shown in yellow.  C) A magnification of the BRCA1 BRCT/BACH1 binding 
pocket.  The consensus sequence for BRCA1 BRCT recognition of 
phosphoproteins is 990pSer-X-X-Phe993.  The BRCA1-binding region of a 
phosphopeptide derived from BACH1 is shown.  Phospho-Ser990 (pS990) 
interacts with Ser1655 and Lys1702 of BRCA1, which form a basic pocket.  
The 3+ Phe993 fits into a hydrophobic pocket created by the two BRCT 
domains (Phe1704, Met1775, Leu1839). Lysine 995 (K995) forms a salt 
bridge with Asp1840 and Glu1836.  Rendering of B and C was generated 
using Visual Molecular Dynamics (VMD) [62].  Structural model in B and C 
is derived from PDB accession number 1T15.   
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Clinical Implications 
 
Structural biology has greatly increased our knowledge of 
BRCA1 structure and function.  Of clinical relevance, atomic 
resolution models have elucidated how BRCA1 missense mutations 
affect structure (see Table 1), with direct implications for 
understanding disease pathogenesis. For example, the x-ray structure 
of the V1809F mutant revealed at the molecular level how this 
mutation disrupts phosphoprotein binding, indicating a mechanism 
by which this mutation leads to loss of function and increased cancer 
risk [15].  
Determining the structure of BRCA1 also has implications for 
the development of future therapeutic treatments.  PARP (poly 
(ADP-ribose) polymerase) inhibitors have been shown to be effective 
in treating BRCA1-mutated tumors.  PARP is activated by DNA 
single strand breaks (SSBs) to form long, branched ADP-ribose chains 
that act as scaffolds to recruit other proteins involved in base excision 
and SSB repair.  These proteins then resolve the SSB.  PARP 
inhibition leads to accumulation of SSBs, followed by collapse of 
replication forks, and finally formation of DSBs [68].  As previously 
described, BRCA1 is a major component of the homologous repair 
(HR) pathway that is responsible for resolution of DSBs.  PARP 
inhibition is especially effective in tumors and cell lines lacking 
homologous repair (HR) activity such as BRCA1-mutated tumors.  
The RING domain of BRCA1 has been shown to be partly 
responsible for sensitivity of tumors to the PARP inhibitor olaparib, 
and this is due to inhibition of BRCA1/BARD1 interaction as well 
as the BRCA1/E2 ligase interaction [69].  Therefore a rationally 
designed drug that targets the BRCA1/BARD1 or BRCA1/E2 
interface, thus inactivating the HR activity, may sensitize tumors to 
PARP inhibition. BRCA1 activity is also regulated by cyclin-
dependent kinase-1 (Cdk1).  Phosphorylation of BRCA1 by Cdk1 
promotes the association of BRCA1 to sites of DNA damage [70]. 
Inhibition of Cdk1 potentiates the sensitivity of cancer cells to PARP 
inhibitors by reducing BRCA1 recruitment and subsequent repair of 
DSBs [71].  Thus, drugs indirectly targeting BRCA1 activity also have 
promise as anti-neoplastic agents when combined with PARP 
inhibitors.  
Drugs targeting the BRCA1 BRCT phosphopeptide binding 
domain may also have therapeutic potential.  The structure of the 
BRCA1 BRCT domain with phosphopeptides derived from both 
CtIP and BACH1 have been determined (See Table 1) [16], [18].  
The BRCA1/CtIP interaction controls the G2/M transition 
checkpoint, while the BRCA1/BACH1 interaction controls the G2 
accumulation checkpoint [58].  As suggested by Varma et. al., a 
rationally designed drug that inhibits phosphopeptide binding to 
BRCA1 would be expected to disrupt G2 cell cycle arrest, leading to 
genomic instability, apoptosis, and increased susceptibility to 
chemotherapeutic agents [16]. Thus, as the examples above 
demonstrate, structural studies of BRCA1 are essential for 
understanding disease pathogenesis and the discovery of novel 
therapeutics. 
 
Conclusions 
 
The high rate of mutations in specific domains of BRCA1 
suggests that these domains are critical for its tumor suppressor 
activity.  Studies into the structure and function of BRCA1 have 
greatly increased our understanding of the molecular mechanisms 
through which mutations cause predisposition to breast and ovarian 
cancers.  However, more studies are needed to fully understand the 
molecular function of BRCA1.  While structural studies of the RING 
and BRCT domains have greatly increased our knowledge of BRCA1, 
these domains only cover 17% of the BRCA1 primary sequence.  
Structural studies of exons 11-13 as well as the rest of the BRCA1 
protein will be necessary to elucidate the molecular basis by which 
mutations in these domains lead to cancer predisposition.   
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